Pharmaceutical Manufacturing Scale-Up & Tech Transfer – Page 47

Site-to-Site Transfer Best Practices for Pharma Operations

Best Practices for Managing Risks During Pharma Site-to-Site Transfers In the complex world of pharmaceutical manufacturing, site-to-site transfers represent a significant operational challenge. These transfers can mean moving products, processes,…

Site-to-Site Transfer Best Practices for Pharma Operations

Following the transfer of a complex biologic product from one manufacturing site to a new facility, the quality control team began noticing several alarming signals:Click to read the full article.

Site-to-Site Transfer Lessons for QA MSAT and Regulatory Teams

During a site-to-site transfer, several signals might indicate that a transfer is not proceeding as expected. Early identification of these symptoms is crucial for timely containment and resolution. Common symptoms…

Site-to-Site Transfer Lessons for QA MSAT and Regulatory Teams

In any site-to-site transfer, early indicators of a problem can often be observed both on the production floor and within laboratory settings. These symptoms may include:Click to read the full…

Regulatory Filing Impact of Scale-Up in Pharmaceutical Manufacturing

Within a manufacturing environment, symptoms of potential regulatory filing impacts during scale-up can manifest in various ways:Click to read the full article.

Regulatory Filing Impact of Scale-Up in Pharmaceutical Manufacturing

Understanding the symptoms that indicate potential regulatory filing impacts during the scale-up process is crucial for early intervention. Common signals include:Click to read the full article.

How Scale-Up Changes Affect CMC Regulatory Filings

Identifying symptoms or signals early in the scale-up process is crucial. Key indicators include: Click to read the full article.

Regulatory Strategy for Pilot to Commercial Scale-Up

During scale-up operations, specific indicators can signal potential regulatory issues. Recognizing these symptoms is the first step in triggering a corrective strategy. Common signals include:Click to read the full article.

Regulatory Strategy for Pilot to Commercial Scale-Up

Identifying symptoms early is crucial for addressing regulatory issues that may arise during scale-up.Click to read the full article.

When Scale-Up Requires Prior Approval or Variation Filing

During a routine production run of an oncology drug, quality control (QC) personnel detected deviations in the potency assays of several batches produced post-scale-up. Initial tests indicated that the potency…

When Scale-Up Requires Prior Approval or Variation Filing

During a recent scale-up at a biopharmaceutical facility, personnel detected several indicators that raised alarm regarding the regulatory integrity of the production process. Key symptoms included:Click to read the full…

How to Document Scale-Up Rationale in Regulatory Submissions

The initial signs of potential issues during scale-up can manifest in various ways in both the manufacturing environment and during laboratory investigations. Common symptoms include:Click to read the full article.